» Articles » PMID: 25462819

Iron Supplementation and Mortality in Incident Dialysis Patients: an Observational Study

Overview
Journal PLoS One
Date 2014 Dec 3
PMID 25462819
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Studies on the association between iron supplementation and mortality in dialysis patients are rare and conflicting.

Methods: In our observational single-center cohort study (INVOR study) we prospectively studied 235 incident dialysis patients. Time-dependent Cox proportional hazards models using all measured laboratory values for up to 7.6 years were applied to study the association between iron supplementation and all-cause mortality, cardiovascular and sepsis-related mortality. Furthermore, the time-dependent association of ferritin levels with mortality in patients with normal C-reactive protein (CRP) levels (<0.5 mg/dL) and elevated CRP levels (≧0.5 mg/dL) was evaluated by using non-linear P-splines to allow flexible modeling of the association.

Results: One hundred and ninety-one (81.3%) patients received intravenous iron, 13 (5.5%) patients oral iron, whereas 31 (13.2%) patients were never supplemented with iron throughout the observation period. Eighty-two (35%) patients died during a median follow-up of 34 months, 38 patients due to cardiovascular events and 21 patients from sepsis. Baseline CRP levels were not different between patients with and without iron supplementation. However, baseline serum ferritin levels were lower in patients receiving iron during follow up (median 93 vs 251 ng/mL, p<0.001). Iron supplementation was associated with a significantly reduced all-cause mortality [HR (95%CI): 0.22 (0.08-0.58); p = 0.002] and a reduced cardiovascular and sepsis-related mortality [HR (95%CI): 0.31 (0.09-1.04); p = 0.06]. Increasing ferritin concentrations in patients with normal CRP were associated with a decreasing mortality, whereas in patients with elevated CRP values ferritin levels>800 ng/mL were linked with increased mortality.

Conclusions: Iron supplementation is associated with reduced all-cause mortality in incident dialysis patients. While serum ferritin levels up to 800 ng/mL appear to be safe, higher ferritin levels are associated with increased mortality in the setting of concomitant inflammation.

Citing Articles

Comparative iron management in hemodialysis and peritoneal dialysis patients: a systematic review.

van Lieshout T, Klerks A, Mahic O, Vernooij R, Eisenga M, van Jaarsveld B Front Nephrol. 2024; 4:1488758.

PMID: 39664943 PMC: 11631840. DOI: 10.3389/fneph.2024.1488758.


High Ferritin and Low Total Iron-Binding Capacity in Plasma Predict All-Cause Mortality During the First 3 Years of Hemodialysis in Patients with End-Stage Chronic Kidney Disease.

Thu H, Nguyen Van H, Nguyen Minh T, Trung K, Le Viet T Int J Gen Med. 2024; 17:105-113.

PMID: 38229881 PMC: 10790587. DOI: 10.2147/IJGM.S446115.


Elevated Ferritin Levels Associated with High Body Fat Mass Affect Mortality in Peritoneal Dialysis Patients.

Lee H, Noh H, An J, Song Y, Kim S, Kim J Nutrients. 2023; 15(9).

PMID: 37432308 PMC: 10180848. DOI: 10.3390/nu15092149.


Iron deficiency in sepsis patients managed with divided doses of iron dextran: a prospective cohort study.

Czempik P, Wiorek A Sci Rep. 2023; 13(1):5264.

PMID: 37002279 PMC: 10066317. DOI: 10.1038/s41598-023-32002-y.


Risk of Infection Associated With Administration of Intravenous Iron: A Systematic Review and Meta-analysis.

Shah A, Donovan K, Seeley C, Dickson E, Palmer A, Doree C JAMA Netw Open. 2021; 4(11):e2133935.

PMID: 34767026 PMC: 8590171. DOI: 10.1001/jamanetworkopen.2021.33935.


References
1.
Koskenkorva-Frank T, Weiss G, Koppenol W, Burckhardt S . The complex interplay of iron metabolism, reactive oxygen species, and reactive nitrogen species: insights into the potential of various iron therapies to induce oxidative and nitrosative stress. Free Radic Biol Med. 2013; 65:1174-1194. DOI: 10.1016/j.freeradbiomed.2013.09.001. View

2.
Horl W . [Anemia and its treatment in peritoneal dialysis patients]. Wien Klin Wochenschr. 2006; 117 Suppl 6:69-72. DOI: 10.1007/s00508-005-0486-9. View

3.
Deicher R, Horl W . Anaemia as a risk factor for the progression of chronic kidney disease. Curr Opin Nephrol Hypertens. 2003; 12(2):139-43. DOI: 10.1097/00041552-200303000-00003. View

4.
Gupta A, Zhuo J, Zha J, Reddy S, Olp J, Pai A . Effect of different intravenous iron preparations on lymphocyte intracellular reactive oxygen species generation and subpopulation survival. BMC Nephrol. 2010; 11:16. PMC: 2933673. DOI: 10.1186/1471-2369-11-16. View

5.
Eschbach J, Adamson J . Iron overload in renal failure patients: changes since the introduction of erythropoietin therapy. Kidney Int Suppl. 1999; 69:S35-43. DOI: 10.1046/j.1523-1755.1999.055suppl.69035.x. View